By enGenes Biotech…
Subscribe to Supplier
Subscribe to Supplier
enGenes Biotech – Advancing Vaccine Innovation at World Vaccine Congress Amsterdam 2025
Vienna, Austria: – Bioprocessing solutions expert enGenes Biotech will share insights into its advanced vaccine development capabilities at the upcoming 2025 World Vaccine Congress in Amsterdam.
The WVC franchise, with annual congresses in Europe and the USA, has become a leading global knowledge-sharing platform for the whole vaccine R&D and manufacturing value chain. enGenes will be an active participant in the many networking events in Amsterdam, detailing the various ways in which it can speed vaccine development. These include support for development of recombinant protein and plasmid DNA bioprocesses and advanced affinity ligand activities.
Driving vaccine development
enGenes Business Development Manager Dr. Ophelia Gevaert will lead the company’s presence in Amsterdam and welcomes pre-event connections to make appointments for face-to-face meetings (see Resources).
Dr. Gevaert commented: “This important congress provides us with a ‘must attend’ opportunity to exchange ideas and foster collaborations that will drive forward the development of new and effective vaccines.”
“We can highlight so many ways in which we can help vaccine developers accelerate from concept to clinic with high-performance bioprocessing built around our proprietary E. coli platforms, such as -eXpress™, -eXcess™, and -eXchange™ that can deliver scalable recombinant production of difficult targets and vaccine antigens. Our antibiotic-free, growth-decoupled processes boost yields and simplify downstream operations,” Dr. Gevaert noted.
Streamlined purification
“We can also provide end-to-end plasmid DNA services, including antibiotic-resistance-marker-free and minicircle options, to support gene-based vaccines and upstream supply for AAV manufacturing.
”Beyond production, we are building a portfolio of capture tools and enzymes to streamline purification, offering high-performance affinity ligands—including protein A solutions—and introducing an endonuclease line to improve pDNA and protein workflows. For next-generation vaccine modalities and conjugate designs, our -eXpand platform enables site-specific incorporation of non-canonical amino acids for precise recombinant protein engineering and click-ready handles,” she added.
“All in all, there is a lot to talk about in Amsterdam,” Ophelia Gevaert concluded.
About enGenes Biotech
With more than a decade of proven expertise, enGenes Biotech develops bioprocesses that consistently outperform conventional approaches. The company’s proprietary technology platforms deliver higher yields, faster timelines, and superior scalability for recombinant proteins, peptides and plasmid DNA production in E. coli. These directly translate into reduced production costs and accelerated market entry. From early concept to industrial process, they enable pharmaceutical, diagnostic and industrial applications to achieve results that set new industry benchmarks at a fraction of the cost.
enGenes Biotech’s expertise spans every step of the biomanufacturing lifecycle: molecular biology, upstream and downstream processing, analytics, process scale-up, product development, and market entry. It can deliver tailored solutions that reduce costs, advance sustainable innovation, and improve customers’ competitive position on the global marketplace.
The company offers development and manufacturing services for recombinant proteins, peptides, and plasmid DNA tailored to the needs of pharmaceutical and industrial biotech companies. Their integrated service portfolio ensures efficiency, quality, and speed in tackling even the toughest challenges. In addition, they are building a portfolio of high-quality and cost-effective products, with an initial focus on endonucleases and protein A-based affinity ligands.
Find out more at: https://www.engenes.cc
About World Vaccine Congress Europe 2025
Billed as Europe’s leading vaccine event, the World Vaccine Congress Europe is the largest and longest-established European meeting on vaccine R&D, covering the whole development value chain involving academia, government and manufacturers,
WVC 2025 will be held over four days with a day of pre-event workshops before the conference opens on 14 October 2025 at the RAI Congress Centre, in Amsterdam, The Netherlands.
The 2025 conference will cover ‘The Start-to-Finish of Vaccines: From immune profiling & clinical development, to global health, supply, and access’ with a multi-track program covering topics such as Clinical Development, Bioprocessing & Manufacturing, and Cancer Immunotherapy. The co-located Exhibition will feature some 150 solutions providers from around the world.
The event is organized by Terrapin with further information at: https://www.terrapinn.com/conference/world-vaccine-congress-europe/index.stm
Resources
Email Ophelia Gevaert to set up meeting in Amsterdam.
Connect with enGenes via the Terrapinn Event App and book a meeting.
The World Vaccine Congress series with their co-located exhibitions are among the world’s leading events dedicated to vaccine development.
Related Articles
